<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24482398</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>209</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness.</ArticleTitle><Pagination><StartPage>1873</StartPage><EndPage>1881</EndPage><MedlinePgn>1873-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jit839</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few studies have prospectively assessed viral etiologies of acute respiratory infections in community-based elderly individuals. We assessed viral respiratory pathogens in individuals &#x2265;65 years with influenza-like illness (ILI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Multiplex reverse-transcriptase polymerase chain reaction identified viral pathogens in nasal/throat swabs from 556 episodes of moderate-to-severe ILI, defined as ILI with pneumonia, hospitalization, or maximum daily influenza symptom severity score (ISS) &gt;2. Cases were selected from a randomized trial of an adjuvanted vs nonadjuvanted influenza vaccine conducted in elderly adults from 15 countries.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Respiratory syncytial virus (RSV) was detected in 7.4% (41/556) moderate-to-severe ILI episodes in elderly adults. Most (39/41) were single infections. There was a significant association between country and RSV detection (P = .004). RSV prevalence was 7.1% (2/28) in ILI with pneumonia, 12.5% (8/64) in ILI with hospitalization, and 6.7% (32/480) in ILI with maximum ISS &gt; 2. Any virus was detected in 320/556 (57.6%) ILI episodes: influenza A (104/556, 18.7%), rhinovirus/enterovirus (82/556, 14.7%), coronavirus and human metapneumovirus (each 32/556, 5.6%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This first global study providing data on RSV disease in &#x2265;65 year-olds confirms that RSV is an important respiratory pathogen in the elderly. Preventative measures such as vaccination could decrease severe respiratory illnesses and complications in the elderly.</AbstractText><CopyrightInformation>&#xa9; The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falsey</LastName><ForeName>Ann R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine, Rochester General Hospital, Rochester, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElhaney</LastName><ForeName>Janet E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>HSN Volunteer Association Chair in Geriatric Research, Advanced Medical Research Institute of Canada, Sudbury, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beran</LastName><ForeName>Jiri</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccination and Travel Medicine Centre, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Essen</LastName><ForeName>Gerrit A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duval</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Inserm CIC, H&#xf4;pital Bichat Claude Bernard National Network of Clinical Investigation in Vaccinology (REIVAC), France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esen</LastName><ForeName>Meral</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Tropenmedizin, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galtier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Network of Clinical Investigation in Vaccinology (REIVAC), France Inserm CIC, CHRU de Montpellier, H&#xf4;pital Saint Eloi, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gervais</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Q&amp;T Research Sherbrooke, Sherbrooke, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Shinn-Jang</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan National Yang-Ming University School of Medicine, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremsner</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Tropenmedizin, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launay</LastName><ForeName>Odile</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>National Network of Clinical Investigation in Vaccinology (REIVAC), France Inserm, CIC BT505 Universit&#xe9; Paris Descartes, Assistance Publique H&#xf4;pitaux de Paris, Groupe Hospitalier Paris Centre, CIC de Vaccinologie Cochin/Pasteur, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroux-Roels</LastName><ForeName>Geert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Vaccinology, Ghent University and University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNeil</LastName><ForeName>Shelly A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Canadian Center for Vaccinology and Capital Health, Dalhousie University Health Sciences Centre, Halifax, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowakowski</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Family Medicine Centre, Lubart&#xf3;w, Poland Department of Gynaecology and Oncologic Gynaecology, Military Institute of Medicine, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardus</LastName><ForeName>Jan Hendrik</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>GGD Rotterdam-Rijnmond, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Palacios</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n Salvador Zubir&#xe1;n, Tlalpan, M&#xe9;xico City, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St Rose</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Vaccines, Wavre, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devaster</LastName><ForeName>Jeanne-Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Vaccines, Rixensart, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oostvogels</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Vaccines, Wavre, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durviaux</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Vaccines, Wavre, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Vaccines, Wavre, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="N">Respiratory Syncytial Virus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012136" MajorTopicYN="N">Respiratory Syncytial Viruses</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">polymerase chain reaction</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">respiratory infection</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>1</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24482398</ArticleId><ArticleId IdType="pmc">PMC4038137</ArticleId><ArticleId IdType="doi">10.1093/infdis/jit839</ArticleId><ArticleId IdType="pii">jit839</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 2008;23:64&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400689</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuno O, Kataoka H, Takenaka R, et al. Influence of age on symptoms and laboratory findings at presentation in patients with influenza-associated pneumonia. Arch Gerontol Geriatr. 2009;49:322&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19150140</ArticleId></ArticleIdList></Reference><Reference><Citation>Govaert TM, Dinant GJ, Aretz K, Knottnerus JA. The predictive value of influenza symptomatology in elderly people. Fam Pract. 1998;15:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9527293</ArticleId></ArticleIdList></Reference><Reference><Citation>She RC, Polage CR, Caram LB, et al. Performance of diagnostic tests to detect respiratory viruses in older adults. Diagn Microbiol Infect Dis. 2010;67:246&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132674</ArticleId><ArticleId IdType="pubmed">20542205</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis. 2010;50:747&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826599</ArticleId><ArticleId IdType="pubmed">20121411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138033</ArticleId><ArticleId IdType="pubmed">21435708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jartti L, Langen H, S&#xf6;derlund-Venermo M, Vuorinen T, Ruuskanen O, Jartti T. New respiratory viruses and the elderly. Open Respir Med J. 2011;5:61&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134957</ArticleId><ArticleId IdType="pubmed">21760867</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15858184</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13:371&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88938</ArticleId><ArticleId IdType="pubmed">10885982</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 1997;315:1060&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127683</ArticleId><ArticleId IdType="pubmed">9366736</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhaney J, Beran J, Devaster J-M, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013;13:485&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">23518156</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne RH, Norquist JM, Elsworth GR, et al. Development and validation of the Influenza Intensity and Impact Questionnaire (FluiiQTM) Value Health. 2011;14:687&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839407</ArticleId></ArticleIdList></Reference><Reference><Citation>Vesikari T, Beran J, Durviaux S, et al. Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. J Clin Virol. 2012;53:22&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22079305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahony J, Chong S, Merante F, et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol. 2007;45:2965&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045291</ArticleId><ArticleId IdType="pubmed">17596360</ArticleId></ArticleIdList></Reference><Reference><Citation>Merante F, Yaghoubian S, Janeczko R. Principles of the xTAG respiratory viral panel assay (RVP Assay) J Clin Virol. 2007;40(Suppl 1):S31&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128903</ArticleId><ArticleId IdType="pubmed">18162252</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleiss J, Levin B, Paik M. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 2003.</Citation></Reference><Reference><Citation>Falsey AR, McCann RM, Hall WJ, Criddle MM. Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults. J Am Geriatr Soc. 1996;44:71&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlinaric-Galinovic G, Falsey AR, Walsh EE. Respiratory syncytial virus infection in the elderly. Eur J Clin Microbiol Infect Dis. 1996;15:777&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9072495</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe ASA, Carraro E, Candeias JMG, et al. Viral etiology among the elderly presenting acute respiratory infection during the influenza season. Rev Soc Bras Med Trop. 2011;44:18&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21340401</ArticleId></ArticleIdList></Reference><Reference><Citation>Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis. 1999;179:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">9841818</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanzer DL, Langley JM, Tam TWS. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respi Viruses. 2008;2:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4634329</ArticleId><ArticleId IdType="pubmed">19453488</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin MR, Coffey CS, Neuzil KM, Mitchel EF, Jr, Wright PF, Edwards KM. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med. 2002;162:1229&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12038940</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>